Funding round completed
Dutch biotech ProFibrix BV has announced the closing of a €8 million second round of financing led by new investor Gilde Healthcare Partners and joined by existing investor Index Ventures. Dirk Kersten from Gilde will join the company’s Supervisory Board.
Jaap Koopman, Chief Executive Officer, said, “The proceeds of the financing will be applied to the ongoing clinical development of our lead product Fibrocaps, and to the preclinical development of our pipeline products.”
Fibrocaps, a mixture of two essential blood clotting proteins fibrinogen and thrombin, is a dry powder topical tissue sealant that rapidly stops bleeding after or during surgery. Fibrocaps has major advantages over existing liquid tissue sealants in that it is ready for immediate use, is stable at room temperature, and is highly effective and fast-acting. The product is currently in a Phase II clinical trial in the Netherlands with results expected end of 2009.
Kersten said, “We believe ProFibrix’ breakthrough fibrinogen technology is well positioned to play an important role in the highly attractive haemostasis and regenerative medicine markets.”
ProFibrix expects to submit an application to carry out a US trial in 2010.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
Follow where the public and private R&I money is going and which collaborative opportunities you can pursue.
